Human papillomavirus (HPV) has been shown to be a causative agent in the development of anogenital warts, intraepithelial neoplasia, and invasive cancers. A quadrivalent HPV vaccine has been approved recently for use in young women ages 11 to 26 years, with the intent of protecting against the most common subtypes of HPV implicated in anogenital disease (types 6, 11, 16, 18).
This symposium was held on Monday, October 15, 2007, at the American Society for Reproductive Medicine 2007 Annual Meeting in Washington, DC, to explore the recent information regarding the efficacy of the vaccine, as well as discuss controversies regarding who else should be vaccinated, whether vaccination should be mandated, and if there is a role for the vaccine in protecting against HPV-related disease in other sites of the body.
At the conclusion of this symposium, participants should be able to:
•Summarize the current recommendations for clinical use of the quadrivalent human papillomavirus vaccine
•Discuss recent epidemiological data concerning the varying degree of risk of cervical neoplasia according to type-specific HPV infection
•Describe the influence of age and gender on HPV vaccination
 |
HPV: Clinical Significance
Samantha M. Pfeifer, MD
Associate Professor of Obstetrics and Gynecology
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
|
| |
 |
HPV Vaccination: Influence of Age and Gender
Mark Spitzer, MD
Chairman, Obstetrics and Gynecology
Brookdale University Hospital and Medical Center
Professor of Clinical Obstetrics and Gynecology
Weill Medical College of Cornell University
New York, New York
|
| |
 |
Lessons Learned From Implementation of Hepatitis B Immunization in the United States
John W. Ward, MD
Division of Viral Hepatitis
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
Atlanta, Georgia
|
Slides/Transcript
CME Posttest and Evaluation
1.5 CME credits available
Click here
All speakers were required to complete a disclosure of commercial and financial relationships with manufacturers of pharmaceuticals, laboratory supplies, or medical devices and with commercial providers of medically related services. These disclosures were reviewed and potential conflicts of interest resolved by the Subcommittee on Standards of Commercial Support of the Continuing Medical Education Committee of the American Society for Reproductive Medicine. The disclosures are listed in the presentations.
Supported by an educational grant from Merck.
Back to top |
